Marlboro Maker Invests $1.7 Billion in Cannabis

The cannabis industry announced a groundbreaking $1.7 billion megadeal with big tobacco that has the sector on the upswing last week.

Marlboro maker Altria Group (MO), one of the largest tobacco companies in the world, announced a $1.7 billion investment in Cronos Group (CRON), one of Canada’s largest cannabis companies.

Here are some more details from Bloomberg.

Altria has agreed to take a 45 percent stake in Toronto-based marijuana producer Cronos Group Inc., marking a major tobacco company’s first foray into cannabis. It has the option to take majority control in the future.

With U.S. smoking rates falling fast, Richmond, Virginia-based Altria is under pressure to find new avenues to expand. Marijuana is now allowed in an increasing number of states but is still illegal on the federal level in the U.S. That makes Canada, which legalized recreational use in October, a large laboratory for the nascent industry.

“We believe cannabis is an excellent strategic fit for tobacco,” Jefferies analyst Owen Bennett said in a research note earlier this week. It’s a logical fit, because “big tobacco knows how to cultivate crop, knows how to deal with regulators, they are at the forefront of vaporization technology, and they also arguably have less reputational risk than other fast-moving consumer goods,” he said.

The good news gave Cronos a nice boost – shares jumped 25% and settled just shy of the 52-week high.


This $1.7 Billion Mega Deal is a Big Win for the Cannabis Industry

This deal clocks in as the second largest deal in the history of the cannabis industry, behind Constellation’s (STZ) $3.8 billion investment in Canopy.

It also marks the first time that big tobacco has invested directly in cannabis.

And finally, it shows a clear trend of big alcohol and big tobacco making billion-dollar investments in early cannabis leaders.

Like analysis from Michael Vodicka of Cannabis Stock Trades?

To get the latest analysis as soon as it is released, please subscribe to our free weekly newsletter

Cannabis Stock Trades provides investors reliable information on the cannabis industry and the small group of hidden companies that are cashing in on this explosive trend.

It is the third megadeal the cannabis industry has seen with big alcohol and big tobacco, and I think there’s a high probability there will be many more coming down the pike.

Now, the natural question is – which cannabis company will be the next to secure a billion dollar mega deal? Because that can be great for shares in the short run and fuel big sales growth in the long run.

I see another early leader in Canada that looks like a great target.

  • Early and growing international presence.
  • Low-cost producer.
  • Long-term potential in the United States.

Aurora Cannabis (ACB) is one of the largest Canadian cannabis companies with a market value of $6.2 billion and an early leader in the global cannabis industry.

Aurora looks ripe for a big investment. It owns and operates some of the largest and most impressive cultivation facilitates in the world.

Aurora Sun

  • Located in Medicine Hat, the sunniest city in Canada, with more than 2,500 hours of sunshine per year.
  • 1,200,000 square foot (over 21 football fields). The footprint of Aurora Sun will be 50% larger than Aurora’s Sky
    850,000 square feet of flowering space built in compliance with European Union (EU) Good Manufacturing Practices (GMP) standards, ensuring product from the facility can be exported anywhere in the world where cannabis is nationally legal for medical or (in future) adult-usage purposes.
  • Production capacity of 150,000+ kg per year.

Aurora Sky

  • 800,000 square foot.
  • 100,000+ kg per annum cultivation capacity.
  • Strategically located at Edmonton International Airport, which provides immediate access to domestic and international courier services, customs, security and a whole host of other logistics and infrastructure benefits.

Aurora’s huge network of cannabis greenhouses makes it one of the lowest-cost producers in the world.

Aurora is also one of the most international cannabis companies. Aurora has an early and growing presence in some of the fastest growing cannabis markets in the world. Aurora currently has operations in 18 countries, including high-growth regions in Europe and South America.

Last week, Aurora announced it is expanding in Mexico, buying the country’s first federally licensed importer of THC products.

Farmacias recently became Mexico’s first and only federally licensed importer to date of raw materials containing THC, gaining the necessary licenses, facilities, and permissions to import raw THC material, and manufacture, store, and distribute medical cannabis products containing over 1% THC. This transaction firmly establishes Aurora’s first-mover advantage in one of the world’s most populous countries, where more than 130 million people will have federally legal access to a range of Aurora’s non-flower medical cannabis products containing THC.

Aurora Cannabis to Acquire Mexico’s Farmacias Magistrales S.A.

Aurora ripped higher at the end of 2017. 2018 has been mostly rangebound in a wide range between the 2018 high and low.


Looking forward, I see a lot of potential for Aurora. The company looks like a solid target for a billion-dollar investment from big alcohol or big tobacco.

Timing will be everything for this trade.


Michael Vodicka
Editor, Cannabis Stock Trades

The information contained in this post is for informational and educational purposes only. The trading ideas and stock selections represented on the Cannabis Stock Trades website are not tailored to your individual investment needs. Readers and members are advised to consult with their financial advisor before entering into any trade. Cannabis stocks carry a certain level of risk and we accept no responsibility for any potential losses. All trades, patterns, charts, systems, etc. discussed are for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher.